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Abstract
Background: Guidelines for the management of atrial fibrillation (AFib) recommend an-
tithromboembolic treatment strategies for patients with AFib and acute coronary syndrome 
(AFibACS). Our study assessed how current guidelines are implemented in the metropolitan 
area of Berlin and which therapeutic options were chosen in light of stroke and bleeding risk 
in everyday practice.
Methods and Results: Between April 2008 and January 2012, we included 1,295 AFibACS 
patients in the AFibACS Registry, as part of the Berlin Myocardial Infarction Registry. Mean 
age of the patients was 76 years with numerous comorbidities (15.4% former stroke, 35.0% 
renal failure, 43.5% diabetes, 92.8% hypertension). Of all the patients, 888 were treated with 
stent implantation, 91 with balloon angioplasty, and 316 conservatively. Overall mortality was 
11.6%, and 8.3% in stented patients. At hospital discharge, triple therapy was administered 
to 49.9% of stented cases. After adjustment, odds of receiving triple therapy were lower with 
increasing age and renal failure. Odds were higher after stent implantation, with a higher 
CHA2DS2-VASc score, and with any AFib category compared to initially diagnosed AFib. Be-
tween 2008 and 2011, triple therapy increased from 33.3% to 49.8% for stented patients and 
did not change significantly for those treated conservatively or with balloon angioplasty.
Conclusions: These data suggest that in AFibACS patients, antithrombotic treatment focused 
on dual antiplatelet therapy for ACS, rather than on anticoagulation therapy for stroke pre-
vention. Factors influencing therapy at discharge were age, renal failure, stent implantation, 
AFib category, and CHA2DS2-VASc score. During the study period, triple therapy increased for 
stented patients. (Cardiol J 2014; 21, 5: 465–473)
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Introduction
Atrial fibrillation (AFib) is the most common 
cardiac arrhythmia and it is found in 1–2% of the 
general population. AFib increases the risk of 
stroke 5-fold and is responsible for one-fifth of all 
incidents of stroke — often severe cases with a high 
degree of disability and a risk of death double to 
that of patients with other causes of stroke [1, 2]. 
For prevention of stroke, patients with AFib recei-
ve antithrombotic therapy (level of evidence Ia in 
guidelines) which reduces stroke rates by 64% [3]. 
In a recent analysis of a large German database, 
Wilke et al. [4] showed that the use of anticoa-
gulation therapy reduced the stroke rate by 74%.
Patients with AFib and acute coronary syn-
drome (ACS) pose an even greater challenge. For 
prevention of stroke, these patients need antico-
agulation therapy, and for prevention of further 
coronary events, they require dual antiplatelet 
therapy as recommended by current guidelines 
[5–7]. However, the combination of anticoagulation 
and dual antiplatelet therapy (triple therapy) may 
dramatically increase the risk of bleeding, with the 
incidence of bleeding being reported from 2% to 
15% [5] and increased bleeding events will lead to 
longer  therapy duration [8]. At the same time, ACS 
patients with major bleeding have greater risk of 
death than patients without bleeding [9, 10].
Considering the dilemma whether anticoagu-
lation medication for stroke prevention on top of 
dual antiplatelet therapy may increase the risk of 
bleeding, strong evidence from adequately powered 
and rigorously conducted trails would be crucial. 
However, existing recommendations are based on 
small samples and show inconsistent findings on 
safety and efficacy. The 20 studies [5] that served 
as the basis for the AFib guideline recommenda-
tions comprised between 27 to 1,247 cases, with 
14 studies having included less than 250 cases and 
15 studies being single-center or dual-center studies.
For AFibACS patients with a low or interme-
diate hemorrhagic risk, guidelines recommend 
triple therapy for 6 months, a combination of an-
ticoagulation and clopidogrel for up to 12 months, 
and anticoagulation lifelong. For AFibACS patients 
with a high hemorrhagic risk, guidelines recom-
mend triple therapy for 4 weeks, a combination of 
anticoagulation and clopidogrel for up to 12 months, 
and anticoagulation lifelong [11, 12]. A United 
States consensus document in comparison to the 
European approach proposes a longer duration of 
triple therapy for patients with low to moderate 
bleeding risk and increased stent thrombosis and 
stroke risk. Trying to avoid thromboembolic com-
plications seems to be greater in North America 
compared to Europe, where bleeding was more of 
a concern [13, 14].
Because of the high risk of bleeding, triple 
therapy is under discussion [15]. The WOEST 
Study [16], which included AFib patients treated 
with a stent, and a Danish data [17] analysis with 
AFibACS patients showed that bleeding risk and 
mortality were higher in patients treated with triple 
therapy than those treated with anticoagulation 
medication and clopidogrel alone (double therapy), 
with no difference in stent thrombosis and throm-
boembolic risk. Also, a small study by Yang et al. 
[18] showed that a dual therapy with aspirin and 
prasugrel was more potent than a triple therapy 
with aspirin, clopidogrel and cilostazol.
Our study aimed at showing how guidelines 
were implemented in the metropolitan area of 
Berlin and which therapeutic options were taken 
in light of stroke and bleeding risk in everyday 
practice. Rubboli et al. [19] were recently able to 
show that the management of patients with AFib 
and coronary stenting was variable across Europe 
and only partially adherent to guidelines.
Methods
The Berlin Myocardial Infarction Registry 
(BMIR) is a prospective registry, which has conti-
nuously been collecting data on treatment of ACS 
patients in Berlin hospitals since 1999. Our study 
was carried out on top of the ongoing BMIR [20].
Between April 2008 and January 2012, we 
collected data on 11,068 ACS patients admitted to 
19 hospitals in Berlin within 24 h after ACS symp-
tom onset. ACS was defined as type I myocardial 
infarction, as universally defined [21]. In our study, 
we included only those 1,295 ACS patients, who in 
addition to ACS suffered from non-valvular AFib. 
AFib data were collected and categorized according 
to the presentation of arrhythmia: first-diagnosed, 
paroxysmal, persistent, long-standing persistent, 
and permanent AFib [11].
Regular monitoring and peer review took place 
within the BMIR, and site audits were performed in 
the participating hospitals to ensure that patients are 
consecutively included in the Registry. Patients were 
also selected randomly from every institution, with 
source-data verification in 7.5% of patients. Data entry 
was performed at the Technische Universität Berlin. 
All entries were double-checked for errors and incon-
sistencies. In cases of missing data, institutions were 
asked to provide the additional necessary information.
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Patients’ data were collected anonymously. 
The data registry was approved by the Berlin Board 
for Data Privacy Monitoring. The study protocol 
conformed to the ethical guidelines of the 1975 
Declaration of Helsinki.
Data collection
For the AFibACS Registry, data were collected 
in each institution on hardcopy or electronic que-
stionnaires by trained cardiovascular specialists, 
and were subsequently processed on a pseudony-
mized basis. A booklet with detailed information 
on definitions and special aspects of data entry 
was available in every participating hospital. The 
main sections of the questionnaire covered demo-
graphic data (age, sex), pre-existing risk factors 
(arterial hypertension, smoking, diabetes mellitus, 
hypercholesterolemia > 200 mg/dL), and medical 
history. Congestive heart failure and renal failure 
(with Crea < 2 mg/dL), as well as left ventricular 
function were diagnosed on admission by the at-
tending physician.
Data on the pre-hospital phase and on patient 
findings at initial presentation were also collected: 
e.g., blood pressure, heart rate, and cardiogenic 
shock at admission. The attending physicians re-
corded the type of AFib, CHA2DS2-VASc, and HAS-
-BLED scores, as well as treatment, complications, 
outcome, and medication (including anticoagulation 
medication at hospital discharge).
Statistical methods
Data are presented as percent values, mean 
values with standard deviation, and median values 
with first and third quartiles. We applied Pearson’s 
c2 test for univariate comparison of nominal data. 
We performed the c2 test for trend of categorical 
variables. We performed the t-test for age. Sig-
nificance was assumed for p < 0.05. All tests of 
statistical significance were 2-tailed.
We applied logistic regression to adjust for age 
(in years) and female gender, and for those variab-
les that showed a significant influence on triple 
therapy in univariate analysis: renal failure, stent 
implantation, type of AFib (paroxysmal compared 
to new-onset AFib, and persistent or permanent 
compared to new-onset AFib), and CHA2DS2-VASc 
score as a continuous variable.
Medication at hospital discharge was analyzed 
for all patients discharged alive from the hospital, 
and was defined as the following:
 — DAPT — patients who received only dual 
antiplatelet therapy with aspirin and a P2Y12 
inhibitor;
 — triple therapy — patients who received DAPT 
and anticoagulation medication with either 
a vitamin K antagonist, heparin, or new direct 
oral anticoagulants;
 — double therapy — patients with a single anti-
platelet drug (aspirin, clopidogrel, prasugrel, 
or ticagrelor), and one anticoagulative drug 
(phenprocoumon, heparin, or new direct oral 
anticoagulants);
 — mono therapy — patients with aspirin or clo-
pidogrel only;
 — rest — other combinations with < 2% (in-




A total of 1,295 AFibACS patients were col-
lected during a 46-month study period, which com-
prised 11.7% of all ACS patients enrolled in the 
BMIR (2008: 8.2% and 2011: 14.7% of all ACS 
patients). With a mean age of 75.6 years, the AFib 
ACS patients were older than all ACS patients (66.5 
years), and the percentage of women (38.3%) was 
higher than in the ACS patient group (31%). Com-
pared to all ACS patients, they suffered more from 
comorbidities: 15.4% former stroke (for the total 
cohort: 8.1%), 29.5% former ACS (22.6%), 35% renal 
failure (17.2%), 43.5% diabetes mellitus (30.5%), 
45.6% chronic heart failure (14.8%), and 92.8% hy-
pertension on admission (78.2%). An ST-elevation 
myocardial infarction (STEMI) was present in 31.5% 
compared to 45.5% in all ACS patients, with 8% hav-
ing experienced cardiogenic shock at admission (all: 
6.6%) and 17.1% with a left ventricular function of 
£ 30 compared to 9.9% in all ACS patients.
With respect to the type of AFib, 21.2% were 
categorized as first-diagnosed, 36.0% as paroxy-
smal, 8.7% as persistent, 1.6% as long-standing 
persistent, and 32.6% as permanent AFib.
The CHA2DS2-VASc score was > 1 in 99.2% 
of patients. 69.9% of patients had a high bleeding 
risk with a HAS-BLED score > 2 (Tables 1, 2).
In-hospital treatment and outcome
A total of 888 AFibACS patients were treated 
with stent implantation: 59% with bare metal stents 
(BMS) and 41% with drug-eluting stents (DES). In 91 
patients, only balloon dilatation was performed, and 
316 patients did not undergo intervention. The use of 
BMS or DES was independent of the HAS-BLED sco-
re (HAS-BLED score 0–2: 56% BMS, 44% DES; HAS-
-BLED score > 2: 60% BMS, 40% DES; p = 0.256) 
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and independent of in-hospital bleeding. Patients with 
moderate to severe bleeding (GUSTO criteria) recei-
ved BMS in 66.7% and DES in 33.3% of cases com-
pared to 57.7% with BMS and 42.2% with DES for 
patients with only minor bleeding or without bleeding 
(p = 0.291).
Patients treated with stent, balloon angioplasty 
only, and conservatively differed in age, sex, comor-
bidities, and STEMI (Table 3). They also differed 
in outcome: 8.3% of patients treated with a stent 
died in the hospital compared to 13.2% with ballo-
on angioplasty and 20.3% treated conservatively 
(p < 0.001). Overall death rate was 11.6%.
Hospital discharge medication
Figure 1 depicts discharge medication. With 
a majority of patients on DAPT, main determinants 
Table 3. Baseline characteristics of atrial fibrillation and acute coronary syndrome patients treated with 
stent, balloon angioplasty, or conservatively.







Age [years] 74 76 80 < 0.001
Women 34.6% 33.0% 50.3% < 0.001
ST elevation myocardial infarction 36.8% 37.8% 15.0% < 0.001
Diabetes mellitus 43.4% 42.9% 44.0% 0.861
Hypertension 92.7% 92.3% 93.4% 0.714
Renal failure 30.3% 37.8% 47.3% < 0.001
Coronary heart disease 42.8% 56.0% 50.6% 0.008
Former acute coronary syndrome 28.1% 45.5% 28.9% 0.450
Former stroke 14.0% 11.1% 20.6% 0.0009
Atrial fibrillation permanent 29.6% 37.2% 40.1% < 0.001
CHA2DS2-VASc score (7–9) 10.9% 12.1% 19.1% < 0.001
HAS-BLED score > 2 66.9% 70.3% 77.9% < 0.001
*c2 test for trend 
Table 2. Number of atrial fibrillation and acute 
coronary syndrome patients according to HAS-
-BLED score.
HAS-BLED score No. (%) of patients
Score 0 7 (0.5%)
Score 1 84 (6.5%)
Score 2 299 (23.1%)
Score 3 488 (37.7%)
Score 4 311 (24.1%)
Score 5 89 (6.9%)
Score 6 15 (1.2%)
Score 7 0 (0%)
Score 8 0 (0%)
Score 9 0 (0%)
Table 1. Number of atrial fibrillation and acute  
coronary syndrome patients according to 
CHA2DS2-VASc score.
CHA2DS2-VASc score No. (%) of patients
Score 0 0 (%)
Score 1 10 (0.8%)
Score 2 61 (4.7%)
Score 3 160 (12.4%)
Score 4 279 (21.5%)
Score 5 369 (28.5%)
Score 6 249 (19.2%)
Score 7 112 (8.6%)
Score 8 44 (3.4%)
Score 9 11 (0.8%)
were ACS and stent implantation. Dual antithrom-
botic therapy was provided to 96.3% of stented 
patients — of whom approximately half received 
additional anticoagulation medication. HAS-BLED 
score 0–2 compared to a score > 2 did not show 
any differences between the different categories, 
which may be seen in Figure 1.
Patients on triple therapy after stent place-
ment (n = 406) received phenprocoumon in 55%, 
heparin in 43%, and dabigatran in 2% of cases 
indicating anticoagulation therapy. Those patients 
treated with balloon angioplasty (n = 35) received 
phenprocoumon in 40% and heparin in 60% of 
cases, those treated conservatively (n = 50) were 
on phenprocoumon in 42% and on heparin in 58%.
Prescription of triple therapy at hospital dis-
charge depended on age, renal failure, stent implan-
468 www.cardiologyjournal.org
Cardiology Journal 2014, Vol. 21, No. 5
tation, AFib category, and CHA2DS2-VASc score 
(Table 4). According to the odds ratios (OR), stent 
implantation, and age had the greatest association 
with triple therapy after adjustment by logistic re-
gression analysis. Another major factor of influence 
was the CHA2DS2-VASc score. For each increasing 
additional score point, the chance of receiving triple 
therapy rose by OR = 1.22.
The HAS-BLED score (0–2 vs. > 2) did not 
show a significant influence on the prescription of 
triple therapy in the logistic regression analysis 
(OR 1.15, 95% CI 0.84–1.57). Also, moderate to 
severe in-hospital bleeding did not significantly 
influence prescription of triple therapy (results 
not shown).
Chronological changes in therapy
Patients who were treated with a stent re-
ceived triple therapy more often in the period 
2011–2012 (58.1%) than in 2008 (39.8%) (Fig. 2). 
An increase was not observed in patients treated 
conservatively or with balloon angioplasty. A sig-
nificant share of stent-treated patients were on 
heparin at hospital discharge (Fig. 3). Dabigatran 
played only a minor role in 2011–2012 for patients 
treated with a stent.
Discussion
We collected data from 1,295 AFibACS pa-
tients, who comprised 11.7% of all ACS patients 
collected within the BMIR in the respective period. 
Our figures correlate well with other studies re-
porting that between 6% and 21% of patients with 
ACS suffer from AFib [22].
There was an increase of AFibACS patients 
observed between 2008 and 2011. Although the cau-
ses of this increase remain unclear, we may assume 
it happened due to heightened awareness for AFib 
within our ACS population. An increased awareness 
for AFib was also the assumption put forward by 
Schnabel et al. [2]. Stefansdottir et al. [23] showed an 
increase in prevalence and incidence for patients with 
AFib for Iceland, and Ahmad and Kirchof [24] argued 
in a recent Editorial in “Circulation” that prevalence 
and incidence of AFib increase as the populations 
get older and that improved treatment of patients 
with other cardiac disorders than AFib, i.e. ACS, will 
prolong the lives of the patients at risk of AFib.
Table 4. Factors influencing the prescription 
of triple therapy at discharge for patients with 
CHA2DS2-VASc > 1 (results of a logistic regres-
sion analysis).
Variables adjusted for OR 95% CI
Age [years] 0.98 0.96–0.994
Women 0.82 0.60–1.10
Stent implantation 3.00 2.21–4.06
Renal failure 0.74 0.55–0.98
AFib first-diagnosed  
(reference)
– –
AFib paroxysmal 1.73 1.20–2.47
AFib pers./perm. 2.25 1.57–3.23
CHA2DS2-VASc  
(as a continuous variable)
1.20 1.06–1.35
HAS-BLED score (0–2 vs. > 2) 1.15 0.84–1.57
OR — odds ratio; CI — confidence interval; AFib — atrial fibrilla-
tion; pers. — persistent; perm. — permanent
Figure 1. Antithrombotic therapy at hospital discharge for patients with CHA2DS2-VASc score > 1 treated with bare metal 
stents (BMS) or drug-eluting stents (DES), balloon angioplasty, or conservatively according to HAS-BLED score (in %).
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AFibACS patients, as high-risk group  
of patients
In our study, AFibACS patients were in average 
older than patients with ACS alone. They were also 
multimorbid to a greater degree and had a higher in-
-hospital death rate. Similar data were published by 
the ACTION Registry-GWTG [25], with AFibACS 
patients being on average of 78 years of age, having 
a history of hypertension in 84.7% of cases, diabetes 
mellitus in 38.4%, former ACS in 34.9%, coronary 
heart disease (CHD) in 34.8%, and former stroke 
in 16.3%. They also demonstrated a CHADS2 score 
< 1 in 3.7% of cases and died in hospital in 9.9%. 
The GRACE registry [26] compared ACS patients 
with new-onset and pre-existing AFib. The average 
age of these patients was from 72 to 75. With the 
combination of new-onset and pre-existing AFib 
patients in GRACE, the AFibACS patients had 
a history of hypertension in 71% of cases, of diabe-
tes mellitus in 29%, of former ACS in 37%, and of 
CHD in 24%. They died in the hospital in 11.2% of 
cases. These data were very similar to our results. 
Patients’ characteristics in our context compared 
well with that of previously published registry data 
underscoring that AFibACS patients constitute 
a high-risk group.
In-hospital treatment
We divided our AFibACS patients into three 
groups: those who received interventional reper-
Figure 3. Anticoagulation in stent-treated atrial fibrillation and acute coronary syndrome patients discharged with 
triple therapy (in %).
Figure 2. Changes over time regarding the prescription of triple therapy in atrial fibrillation and acute coronary syn-
drome patients at hospital discharge, treatment with stent, balloon angioplasty, or conservatively (in %).
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fusion therapy with coronary stenting, those with 
balloon angioplasty, and those treated conserva-
tively. The three groups differed substantially. 
Those treated with a stent were younger and less 
often female. In addition, they suffered less often 
from renal failure, CHD, and former stroke, and 
presented with STEMI more often. Mortality for 
stented patients was 12% lower than for those tre-
ated conservatively (p < 0.001). Although patients 
with high risk of bleeding are recommended to 
receive BMS instead of DES, in our study only 60% 
of patients with a HAS-BLED score > 2 received 
DES. This percentage is lower than the one found 
by Rubboli et al. [19] who showed that 76% of AFib 
patients with coronary stenting receive BMS.
Hospital discharge medication
At hospital discharge, 96.3% of patients tre-
ated with a stent were on DAPT compared to 
53.9% of those treated conservatively (p < 0.001). 
Additional anticoagulation (triple therapy) was 
prescribed only in 49.9% of patients with stent and 
in 19.5% of conservatively treated patients. These 
results are in line with the results of the ACTION 
Registry-GWTG [24]. During years 2008–2009, 
only 15% of all AFibACS patients were discharged 
on triple therapy, whereas 63.5% were on DAPT. 
Lamberts et al. [17], with a Danish cohort of AFib 
ACS patients, demonstrated similar results from 
an earlier period (2000–2009) with triple therapy 
in only 13% of all AFibACS patients, DAPT in 
27%, double in 16%, and mono in 36% of patients 
(8% any other combination). Lamberts et al. [17], 
however, showed that the risk of bleeding was 
higher with triple therapy than with other treat-
ment approaches. This risk may be reflected in 
many physicians’ choice not to administer triple 
therapy to AFibACS patients.
A potential reluctance of hospital-based physi-
cians to make a decision for triple therapy may be 
indicated by the high number of patients receiving 
heparin at discharge (40%). This figure suggests 
that hospital physicians shift the decision to sub-
sequent outpatient care.
Logistic regression analysis identified stent 
placement as one of the major determinants 
of triple therapy at discharge after adjustment 
(OR = 3.0). The results of the logistic regression 
also showed that triple therapy was lower in older 
patients and in patients with renal failure, was 
higher in patients with paroxysmal or persistent/ 
/permanent AFib (as compared to first-diagnosed 
AFib) and higher with a higher CHA2DS2-VASc 
score. For each additional point of the CHA2DS2-
-VASc score, the probability of receiving triple 
therapy increased by OR = 1.22, which indicated 
that the chances of receiving triple therapy were 
2.76 times higher with a score of 9 than with 
a score of 1. Thus, the CHA2DS2-VASc score that 
had been introduced in the new European Society 
of Cardiology (ESC) AFib guidelines in 2010 [11] is 
reflected in everyday practice in Berlin hospitals. 
In contrast, we could not identify if the HAS-BLED 
score had a statistically significant influence on the 
rate of triple therapy at discharge, although it has 
been shown that the HAS-BLED score predicts 
bleeding events with a moderate accuracy [27].
Changes of discharge medication  
in recent years
The number of stent-treated patients recei-
ving triple therapy increased over time, especially 
since 2011. Therefore, the awareness of AFib 
and triple therapy has increased since 2011. In 
August of 2010, new ESC AFib guidelines were 
published, which recommended triple therapy for 
AFibACS patients [11]. In 2011, new direct oral 
anticoagulants were approved for stroke preven-
tion in non-valvular AFib patients (dabigatran 
in August 2011 [28], rivaroxaban in December 
2011 [29], and apixaban in November 2012 [30]). 
In 2012, a focused update on the management of 
AFib was published with a special chapter on novel 
oral anticoagulants [12]. Although, as recorded in 
our registry, dabigatran use was low in 2011, it is 
likely that prescription of dabigatran, rivaroxaban, 
and apixaban will increase with a larger number 
of patients treated by triple therapy with these 
agents. However, as voiced in a recent Editorial 
in the “European Heart Journal” [31], it remains 
unclear whether the new oral anticoagulants 
should be preferred over the standard therapy 
for AFibACS patients. Dedicated randomized 
trials on triple therapy with the new direct oral 
anticoagulants are clearly warranted.
Limitations of the study
Since our data are based on a registry, the 
known limitations of registry data must be taken 
into consideration. These, for example, do not 
allow direct comparison of therapies or their effi-
cacy. We do not have follow-up data after hospital 
discharge on bleeding or stroke or mortality. Our 
data were collected in a metropolitan area of the 
city of Berlin and may therefore not be applicable 
to other regions or rural areas.
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Conclusions
Our present analysis illustrates how patients 
with ACS and AFib were treated under real-world 
circumstances. We were able to show that AFibACS 
patients in Berlin were older than ACS patients 
and multimorbid. Hospital discharge treatment 
focused more on ACS treatment with high rates 
of antithrombotic therapy for patients treated with 
a stent, and with lower rates for patients trea-
ted conservatively or with balloon angioplasty. 
In addition, anticoagulation therapy for stroke 
prevention was administered less often. After 
adjustment, higher age and renal failure lowered 
chances of receiving triple therapy, whereas stent 
implantation, paroxysmal or persistent/permanent 
AFib (as compared to first diagnosed AFib), and 
a higher CHA2DS2-VASc score increased chances of 
receiving triple therapy. Over time, triple therapy 
increased for patients treated with a stent.
Owing to their great risk of stroke, patients 
with ACS and AFib pose a therapeutic challenge in 
cases of treatment with anticoagulation on top of 
dual antiplatelet therapy. An additional great risk is 
the one of bleeding associated with triple therapy. 
Therefore, dedicated randomized trials on triple 
therapy with the new direct oral anticoagulants 
are clearly warranted.
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